(Total Views: 631)
Posted On: 12/24/2022 4:17:14 PM
Post# of 153994
Re: chazzledazzle #131941
One last comment before I sign out for the holiday; wishing all of us well today, tomorrow, and next year!
One of the things I find absolutely astounding about Leronlimab is the paucity of any meaningful side effects. How the designers dodged that bullet is a miracle. Look no further than maraviroc attempting to occupy the same receptor…black box warning etc.
I went in heavy with share acquisition because it has the earmarks of a coin with a Janus mint…opening many doors both for clinical impact but ALSO because the “risk” to opening that door is virtually zero. If you were a cancer patient and it “might work” you would still think twice if it meant your existence turned foul over severe vomiting, life threatening neutropenia or any number of side effects BP can conjure. Would you take aduhelm that “might” arrest the progression of Alzheimer’s but knew you were risking a brain bleed? The hold lift documents must speak to risk benefit…that’s a putt-off for Leronlimab.
One of the things I find absolutely astounding about Leronlimab is the paucity of any meaningful side effects. How the designers dodged that bullet is a miracle. Look no further than maraviroc attempting to occupy the same receptor…black box warning etc.
I went in heavy with share acquisition because it has the earmarks of a coin with a Janus mint…opening many doors both for clinical impact but ALSO because the “risk” to opening that door is virtually zero. If you were a cancer patient and it “might work” you would still think twice if it meant your existence turned foul over severe vomiting, life threatening neutropenia or any number of side effects BP can conjure. Would you take aduhelm that “might” arrest the progression of Alzheimer’s but knew you were risking a brain bleed? The hold lift documents must speak to risk benefit…that’s a putt-off for Leronlimab.
(6)
(0)
